Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs

Journal of Clinical Pharmacology

Volumn 46, Issue 8, 2006, Pages 855-866

  Khosravan, Reza ^a   Wu, Jing Tao ^a   Joseph Ridge, Nancy ^a   Vernillet, Laurent ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Drug drug interaction; Febuxostat; Indomethacin; Naproxen; NSAID; Pharmacokinetics

Indexed keywords

DICLOFENAC; FEBUXOSTAT; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; NAUSEA; NORMAL HUMAN;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GOUT SUPPRESSANTS; HUMANS; INDOMETHACIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAPROXEN; REFERENCE VALUES; THIAZOLES;

EID: 33745926837     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006289848     Document Type: Article

References (35)

1. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-3007.
2. Wortmami RL, Kelley WN. Gout and hyperuricemia. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia: W. B. Saunders; 2001:1339-1376.
3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.
4. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.
5. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-1587.
6. Star VL, Hochberg MC. Prevention and management of gout. Drugs. 1993;45:212-222.
7. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855.
8. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76:1835-1847.
9. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993;241:183-188.
10. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993;250:455-460.
11. Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 1999;104:307-319.
12. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916-923.
13. Kamatani N, Fujimori S, Hada T, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia [abstract]. Arthritis Rheum. 2004;50:S337.
14. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acid. 2004;23:1111-1116.
15. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-2461.
16. Kondo S, Nishimura S, Mochizuki T, et al. Metabolic fate of [14C]-TEI-6720, a novel xanthine oxidase inhibitor: tissue distribution after oral administration in rats, protein binding and metabolism in vivo and in vitro [abstract]. Drug Metab Review. 1995;18:56.
17. Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in human [abstract]. Drug Metab Rev. 2000;32:269.
18. Mayer MD, Khosravan R, Vernillet L, Wu J, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12:22-34.
19. Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE. Kinetics of indomethacin absorption, elimination and enterohepatic circulation in man. J Pharmacokinet Biopharm. 1975;4:255-280.
20. Sugawara Y, Fujihara M, Miura K, Hayashida K, Takahashi T. Studies on the fate of naproxen II: metabolic fate in various animals and man. Chem Pharm Bull. 1978;26:3312-3321.
21. Mason RW, MacQueen EG. Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro. Pharmacol. 1974;12:12-19.
22. Ellis DJ, Martin B. The plasma protein binding properties of a new non-steroidal anti-inflammatory agent [abstract]. Fed Proc. 1971;30:1200.
23. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981;6:245-258.
24. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997;32:268-293.
25. Baber N, Holliday L, Sibeon R, Littler T, Orme MLE. The interaction between indomethacin and probenecid. Clin Pharmacol Ther. 1978;24:298-307.
26. Runkel R, Mroszczak E, Chaplin M, Sevellus H, Segre E. Naproxen-probenecid interaction. Clin Pharmacol Ther. 1978;24:706-713.
27. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the pharmacokinetics of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991;32:17-21.
28. Patel M, Tang BK, Kalow W. (S)oxazepam glucuronidation is inhibited by ketoprofen and other susbstrates of UGT2B7. Pharmacogenetics. 1995;5:43-49.
29. Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. Br J Clin Pharmacol. 1993;36:82-85.
30. Duggan DE, Hogans AF, Kwan KC, McMahon FG. The metabolism of indomethacin in man. J Pharmacol Exp Ther. 1972;181:563-575.
31. Rothermich NO. The fate of rectally administered radioactive indomethacin in human subjects: a preliminary report. Clin Pharmacol Ther. 1971;12:300-301.
32. Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE. Kinetics of indomethacin absorption, elimination and enterohepatic circulation in man. J Pharmacokinet Biopharm. 1975;4:255-280.
33. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005;33:1027-1035.
34. Schumacher HR, Becker MA, Wortmann RL, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study [abstract]. Arthritis Rheum. 2005;52:S680.
35. Rao BR, Rambhau D, Rao VVS. Pharmacokinetics of single dose administration of naproxen at 10:00 and 22:00 hours. Chronobiol Int. 1992;9:1436-1441.